[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Elazar V, Adwan H, Rohekar K, Zepp M, Lifshitz-Shovali R, Berger MR, Golomb G: Biodistribution of antisense nanoparticles in mammary carcinoma rat model. Drug Deliv; 2010 Aug;17(6):408-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biodistribution of antisense nanoparticles in mammary carcinoma rat model.
  • The biodegradable and biocompatible poly(D,L-lactic-co-glycolic acid) copolymer (PLGA) was utilized to encapsulate AS directed against osteopontin (OPN), which is a promising therapeutic target in mammary carcinoma.
  • Whole body biodistribution of OPN AS NP was evaluated in comparison to naked AS, in intact and mammary carcinoma metastasis model bearing rats.
  • Drug levels in intact organs were negligible.
  • [MeSH-major] Antineoplastic Agents / pharmacokinetics. Antisense Elements (Genetics) / pharmacokinetics. Bone Neoplasms. Carcinoma. Drug Carriers / pharmacokinetics. Mammary Neoplasms, Experimental. Nanoparticles / chemistry
  • [MeSH-minor] Animals. Cell Line, Tumor. Delayed-Action Preparations / analysis. Delayed-Action Preparations / chemistry. Delayed-Action Preparations / pharmacokinetics. Delayed-Action Preparations / therapeutic use. Drug Delivery Systems. Female. Humans. Lactic Acid / analysis. Lactic Acid / chemistry. Lactic Acid / therapeutic use. Male. Osteopontin / genetics. Particle Size. Polyglycolic Acid / analysis. Polyglycolic Acid / chemistry. Polyglycolic Acid / therapeutic use. Rats. Rats, Nude. Tissue Distribution. Xenograft Model Antitumor Assays / methods

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. LACTIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20429847.001).
  • [ISSN] 1521-0464
  • [Journal-full-title] Drug delivery
  • [ISO-abbreviation] Drug Deliv
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antisense Elements (Genetics); 0 / Delayed-Action Preparations; 0 / Drug Carriers; 0 / polylactic acid-polyglycolic acid copolymer; 106441-73-0 / Osteopontin; 26009-03-0 / Polyglycolic Acid; 33X04XA5AT / Lactic Acid
  •  go-up   go-down


2. Opitz I, Van der Veen H, Witte N, Braumann C, Mueller JM, Jacobi CA: Instillation of taurolidine/heparin after laparotomy reduces intraperitoneal tumour growth in a colon cancer rat model. Eur Surg Res; 2007;39(3):129-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Instillation of taurolidine/heparin after laparotomy reduces intraperitoneal tumour growth in a colon cancer rat model.
  • OBJECTIVE: To investigate whether irrigation of the abdominal cavity after laparotomy for caecum resection with taurolidine/heparin or adhesion prophylactic substances reduces intraperitoneal tumour growth or the local recurrence rate in a colon carcinoma rat model.
  • METHODS: 60 BDIX rats underwent caecum resection after intraperitoneal inoculation of 1 x 10(4) colon carcinoma cells (DHD/K12/TRb).
  • E-Cadherin expression in the metastatic tissue of animals treated with taurolidine/heparin was significantly decreased (p = 0.016).
  • [MeSH-major] Adenocarcinoma / drug therapy. Anticoagulants / therapeutic use. Antineoplastic Agents / therapeutic use. Colonic Neoplasms / drug therapy. Heparin / therapeutic use. Neoplasm Recurrence, Local / prevention & control. Taurine / analogs & derivatives. Thiadiazines / therapeutic use
  • [MeSH-minor] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / pathology. Animals. Immunohistochemistry. Instillation, Drug. Laparotomy. Male. Neoplasm Metastasis / pathology. Neoplasm Metastasis / prevention & control. Rats. Tissue Adhesions / prevention & control

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. Taurine .
  • Hazardous Substances Data Bank. HEPARIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17337889.001).
  • [ISSN] 0014-312X
  • [Journal-full-title] European surgical research. Europäische chirurgische Forschung. Recherches chirurgicales européennes
  • [ISO-abbreviation] Eur Surg Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Antineoplastic Agents; 0 / Thiadiazines; 1EQV5MLY3D / Taurine; 8OBZ1M4V3V / taurolidine; 9005-49-6 / Heparin
  •  go-up   go-down


3. Ferri N, Beccalli EM, Contini A, Corsini A, Antonino M, Radice T, Pratesi G, Tinelli S, Zunino F, Gelmi ML: Antiproliferative effects on human tumor cells and rat aortic smooth muscular cells of 2,3-heteroarylmaleimides and heterofused imides. Bioorg Med Chem; 2008 Feb 15;16(4):1691-701
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiproliferative effects on human tumor cells and rat aortic smooth muscular cells of 2,3-heteroarylmaleimides and heterofused imides.
  • The antiproliferative activity of the novel molecules was tested against human tumor cells (NCI-H460 lung carcinoma) and rat aortic smooth muscle cells (SMCs).
  • Whereas, in rat SMCs, only the compound 12b was shown to be 10-fold more potent than amonafide.
  • [MeSH-major] Antineoplastic Agents / chemistry. Cell Proliferation / drug effects. Imides / pharmacology. Maleimides / pharmacology
  • [MeSH-minor] Animals. Aorta. Cell Line, Tumor. Cells, Cultured. Humans. Inhibitory Concentration 50. Muscle, Smooth, Vascular / cytology. Muscle, Smooth, Vascular / drug effects. Rats. Structure-Activity Relationship

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18061459.001).
  • [ISSN] 1464-3391
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Imides; 0 / Maleimides
  •  go-up   go-down


Advertisement
4. Holmes EW, Bingham CM, Cunningham ML: Hepatic expression of polymerase beta, Ref-1, PCNA, and Bax in WY 14,643-exposed rats and hamsters. Exp Mol Pathol; 2002 Dec;73(3):209-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The hepatic levels of three protein markers of oxidative stress, polymerase beta, Ref-1, and PCNA, and of the pro-apoptotic protein, Bax, were quantitated after exposure to WY 14,643 (500 ppm in the feed) for 6 or 34 days in a rodent that is susceptible peroxisome proliferator (PP)-induced liver tumors (the Sprague Dawley rat) and in a rodent that is relatively resistant PP-induced liver tumors (the Syrian hamster).
  • Dose-response studies in the rat showed that the hepatic expression of the polymerase beta and Ref-1 were significantly increased after 6 days of exposure to WY 14,643 at levels of 5 and 50 ppm, respectively.
  • The analysis of subcellular fractions of rat liver showed that the pathological increases in the levels of polymerase beta, Ref-1, and PCNA were especially prominent in mitochondria-enriched particulate liver subfractions.
  • Our data are consistent with the hypothesis that the chronic overexpression of mutagenic or oncogenic effectors like polymerase beta and Ref-1 in a setting of increased hepatocyte proliferation and decreased apoptosis may facilitate peroxisome proliferator-induced hepatocellular carcinoma in the rat.
  • [MeSH-major] Carbon-Oxygen Lyases / metabolism. DNA Polymerase beta / metabolism. DNA-(Apurinic or Apyrimidinic Site) Lyase. Liver / drug effects. Peroxisome Proliferators / pharmacology. Proliferating Cell Nuclear Antigen / metabolism. Proto-Oncogene Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2. Pyrimidines / pharmacology
  • [MeSH-minor] Animals. Cell Fractionation. Cricetinae. Dose-Response Relationship, Drug. Endodeoxyribonucleases / metabolism. Immunoblotting. Male. Rats. Rats, Sprague-Dawley. Time Factors. bcl-2-Associated X Protein

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Pirinixic acid .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12565796.001).
  • [ISSN] 0014-4800
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / 1 R03 ES09783-01
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bax protein, rat; 0 / Peroxisome Proliferators; 0 / Proliferating Cell Nuclear Antigen; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Pyrimidines; 0 / bcl-2-Associated X Protein; 86C4MRT55A / pirinixic acid; EC 2.7.7.- / DNA Polymerase beta; EC 3.1.- / Endodeoxyribonucleases; EC 4.2.- / Carbon-Oxygen Lyases; EC 4.2.99.18 / Apex1 protein, rat; EC 4.2.99.18 / DNA-(Apurinic or Apyrimidinic Site) Lyase
  •  go-up   go-down


5. Levine L: Tetrandrine and thapsigargin release arachidonic acid from cells in culture and stimulate prostacyclin production in rat liver cells, but may do so by different pathways. BMC Pharmacol; 2005;5:12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tetrandrine and thapsigargin release arachidonic acid from cells in culture and stimulate prostacyclin production in rat liver cells, but may do so by different pathways.
  • The effects of tetrandrine and thapsigargin on arachidonic acid release from human colon carcinoma and rat liver cells and prostacyclin production by rat liver cells are compared in the current studies.
  • RESULTS: Tetrandrine and thapsigargin stimulate arachidonic acid release from human colon carcinoma and rat liver cells and prostacyclin production in rat liver cells.
  • [MeSH-major] Alkaloids / pharmacology. Arachidonic Acid / metabolism. Benzylisoquinolines / pharmacology. Calcium Channel Blockers / pharmacology. Carcinogens / pharmacology. Liver / drug effects. Thapsigargin / pharmacology. Tumor Cells, Cultured / drug effects
  • [MeSH-minor] Animals. Cells, Cultured. HT29 Cells. Humans. Rats

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Pharmacol Sin. 2002 Dec;23(12):1102-6 [12466047.001]
  • [Cites] Anticancer Drugs. 1998 Jan;9(1):77-81 [9491795.001]
  • [Cites] Eur J Pharmacol. 2003 Apr 11;466(1-2):63-71 [12679142.001]
  • [Cites] FASEB J. 2003 May;17(8):800-2 [12724337.001]
  • [Cites] Oncogene. 2003 May 1;22(17):2674-9 [12730681.001]
  • [Cites] J Natl Cancer Inst. 2003 Jul 2;95(13):990-1000 [12837835.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Jul;4(7):552-65 [12838338.001]
  • [Cites] J Pharmacol Sci. 2003 Jul;92(3):228-36 [12890888.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2003 Aug-Sep;69(2-3):87-97 [12895591.001]
  • [Cites] Drug Discov Today. 2003 Aug 1;8(15):710-6 [12927514.001]
  • [Cites] Trends Pharmacol Sci. 2004 Mar;25(3):120-3 [15058281.001]
  • [Cites] BMC Cancer. 2003 Sep 19;3:24 [14498998.001]
  • [Cites] BMC Pharmacol. 2004 Aug 5;4:15 [15296516.001]
  • [Cites] BMC Cancer. 2004 Aug 13;4:49 [15310397.001]
  • [Cites] Trends Pharmacol Sci. 1998 Apr;19(4):131-5 [9612087.001]
  • [Cites] J Exp Med. 1999 Aug 16;190(4):445-50 [10449515.001]
  • [Cites] Bioorg Med Chem. 1999 Jul;7(7):1273-80 [10465403.001]
  • [Cites] Atherosclerosis. 2004 Dec;177(2):235-43 [15530895.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2001 Jul;65(1):31-5 [11487305.001]
  • [Cites] Glia. 2002 Jun;38(4):281-91 [12007141.001]
  • [Cites] J Ethnopharmacol. 2002 Jul;81(2):225-9 [12065155.001]
  • [Cites] Life Sci. 2002 Sep 13;71(17):2053-66 [12175898.001]
  • [Cites] Int J Oncol. 2002 Dec;21(6):1239-44 [12429973.001]
  • [Cites] Acta Pharmacol Sin. 2002 Dec;23(12):1057-68 [12466042.001]
  • [Cites] Acta Pharmacol Sin. 2002 Dec;23(12):1069-74 [12466043.001]
  • [Cites] Acta Pharmacol Sin. 2002 Dec;23(12):1093-101 [12466046.001]
  • [Cites] J Pharmacol Exp Ther. 1984 Nov;231(2):230-5 [6436471.001]
  • [Cites] J Cancer Res Clin Oncol. 1986;111(3):177-81 [2426275.001]
  • [Cites] Br J Pharmacol. 1988 Jul;94(3):917-23 [3140994.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Apr;87(7):2466-70 [2138778.001]
  • [Cites] Int J Immunopharmacol. 1991;13(8):1117-26 [1814849.001]
  • [Cites] Exp Cell Res. 1994 May;212(1):84-92 [8174645.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6167-75 [7954463.001]
  • [Cites] Life Sci. 1995;56(5):295-306 [7837929.001]
  • [Cites] Cell. 1995 Jun 16;81(6):957-66 [7781071.001]
  • [Cites] Science. 1996 Dec 13;274(5294):1855-9 [8943189.001]
  • [Cites] Biochem Pharmacol. 1997 Mar 21;53(6):773-82 [9113098.001]
  • [Cites] Nat Genet. 1997 Sep;17(1):88-91 [9288104.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):681-6 [9435252.001]
  • [Cites] Curr Med Chem. 2003 Apr;10(8):649-61 [12678784.001]
  • (PMID = 15978132.001).
  • [ISSN] 1471-2210
  • [Journal-full-title] BMC pharmacology
  • [ISO-abbreviation] BMC Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alkaloids; 0 / Benzylisoquinolines; 0 / Calcium Channel Blockers; 0 / Carcinogens; 27YG812J1I / Arachidonic Acid; 29EX23D5AJ / tetrandrine; 67526-95-8 / Thapsigargin
  • [Other-IDs] NLM/ PMC1180457
  •  go-up   go-down


6. Sjogren MH: Thymalfasin: an immune system enhancer for the treatment of liver disease. J Gastroenterol Hepatol; 2004 Dec;19 Suppl 6:S69-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thymalfasin (thymosin-alpha 1) is an immunomodulating agent able to enhance the Th1 immune response.
  • Thymalfasin is responsible for reconstitution of immune function when thymic tissue is given back to thymectomized animals.
  • In addition, thymalfasin has been shown to have efficacy in multiple experimental models of immune dysfunction, mainly, infectious diseases such as hepatitis (woodchuck) and influenza (mouse), and cancer such as melanoma (mouse) and colorectal carcinoma (rat) where thymalfasin has shown antitumor effects.
  • [MeSH-major] Antiviral Agents / therapeutic use. Immunologic Factors / therapeutic use. Liver Diseases / drug therapy. Thymosin / analogs & derivatives
  • [MeSH-minor] Amino Acid Sequence. Animals. Apoptosis / drug effects. Cytokines / metabolism. Histocompatibility Antigens Class I / metabolism. Humans. Lymphocytes / drug effects. Lymphopoiesis / drug effects. Molecular Sequence Data. Virus Replication / drug effects

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Blackwell Publishing Asia Pty Ltd.
  • (PMID = 15546253.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Cytokines; 0 / Histocompatibility Antigens Class I; 0 / Immunologic Factors; 0 / thymalfasin; 61512-21-8 / Thymosin
  • [Number-of-references] 13
  •  go-up   go-down


7. Zhang Y, Mi L, Xiong R, Wang PN, Chen JY, Yang W, Wang C, Peng Q: Subcellular Localization of Thiol-Capped CdTe Quantum Dots in Living Cells. Nanoscale Res Lett; 2009;4(7):606-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These unfunctionalized QDs were well internalized into human hepatocellular carcinoma and rat basophilic leukemia cells in vitro.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20596411.001).
  • [ISSN] 1931-7573
  • [Journal-full-title] Nanoscale research letters
  • [ISO-abbreviation] Nanoscale Res Lett
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Claas C, Wahl J, Orlicky DJ, Karaduman H, Schnölzer M, Kempf T, Zöller M: The tetraspanin D6.1A and its molecular partners on rat carcinoma cells. Biochem J; 2005 Jul 1;389(Pt 1):99-110
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The tetraspanin D6.1A and its molecular partners on rat carcinoma cells.
  • In this paper, we summarize our studies performed on the tetraspanin D6.1A/CO-029/TM4SF3 expressed by rat carcinoma cells.
  • In addition, two other molecules were identified to be part of D6.1A complexes at this higher level of association: type II phosphatidylinositol 4-kinase and EpCAM, an epithelial marker protein overexpressed by many carcinomas.
  • [MeSH-major] Membrane Glycoproteins / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] Animals. Antigens, CD / metabolism. Antigens, CD81. Antigens, CD9. Cell Line, Tumor. Detergents / pharmacology. Multiprotein Complexes / chemistry. Multiprotein Complexes / metabolism. Pancreatic Neoplasms / metabolism. Protein Binding / drug effects. Rats. Solubility / drug effects. Tetraspanins. Urinary Bladder Neoplasms / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 2003 Dec 8;163(5):1167-77 [14662754.001]
  • [Cites] J Lipid Res. 1998 Jun;39(6):1152-61 [9643346.001]
  • [Cites] J Mol Med (Berl). 1999 Oct;77(10):699-712 [10606205.001]
  • [Cites] J Cell Biol. 2000 Feb 7;148(3):591-602 [10662783.001]
  • [Cites] J Biol Chem. 2000 Feb 25;275(8):5370-8 [10681511.001]
  • [Cites] FEBS Lett. 2000 Mar 3;469(1):52-6 [10708755.001]
  • [Cites] J Biol Chem. 2000 Mar 31;275(13):9230-8 [10734060.001]
  • [Cites] Eur J Immunol. 2000 Mar;30(3):900-7 [10741407.001]
  • [Cites] J Cell Biol. 2000 May 15;149(4):969-82 [10811835.001]
  • [Cites] Nat Cell Biol. 2000 Sep;2(9):582-92 [10980698.001]
  • [Cites] Biochem J. 2000 Nov 1;351 Pt 3:629-37 [11042117.001]
  • [Cites] J Biol Chem. 2001 Apr 27;276(17):14329-37 [11278880.001]
  • [Cites] J Biol Chem. 2001 Feb 16;276(7):4853-62 [11087758.001]
  • [Cites] J Biol Chem. 2001 Feb 16;276(7):4940-7 [11087729.001]
  • [Cites] J Biol Chem. 2001 Mar 16;276(11):7974-84 [11113129.001]
  • [Cites] Nat Rev Mol Cell Biol. 2000 Oct;1(1):31-9 [11413487.001]
  • [Cites] J Biol Chem. 2001 Jul 6;276(27):25005-13 [11325968.001]
  • [Cites] Cell Mol Life Sci. 2001 Aug;58(9):1189-205 [11577978.001]
  • [Cites] Mol Biol Cell. 1998 Oct;9(10):2751-65 [9763442.001]
  • [Cites] Biochem J. 1999 May 15;340 ( Pt 1):103-11 [10229664.001]
  • [Cites] J Immunol. 2001 Nov 1;167(9):5115-21 [11673522.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):41165-74 [11479292.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):40545-54 [11504738.001]
  • [Cites] J Hepatol. 2001 Nov;35(5):637-42 [11690710.001]
  • [Cites] J Biochem. 2002 Jan;131(1):39-44 [11754733.001]
  • [Cites] Mol Biol Cell. 2002 Mar;13(3):767-81 [11907260.001]
  • [Cites] J Biol Chem. 2002 Sep 13;277(37):34349-58 [12068006.001]
  • [Cites] Int J Oncol. 2003 Mar;22(3):663-70 [12579322.001]
  • [Cites] Mol Biol Cell. 2003 Feb;14(2):611-24 [12589058.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Apr 25;304(1):107-12 [12705892.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5795-800 [12721375.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2665-74 [12750295.001]
  • [Cites] Cell. 2003 Aug 8;114(3):299-310 [12914695.001]
  • [Cites] Eur J Immunol. 2003 Sep;33(9):2479-89 [12938224.001]
  • [Cites] J Cell Sci. 2003 Nov 1;116(Pt 21):4373-90 [13130099.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Nov;18(11):1309-14 [14535989.001]
  • [Cites] J Cell Biol. 2003 Oct 13;163(1):165-76 [14557253.001]
  • [Cites] Annu Rev Cell Dev Biol. 2003;19:397-422 [14570575.001]
  • [Cites] Exp Cell Res. 2004 Jul 15;297(2):329-47 [15212938.001]
  • [Cites] Br J Cancer. 1978 Jan;37(1):61-6 [619957.001]
  • [Cites] Anal Biochem. 1984 Apr;138(1):141-3 [6731838.001]
  • [Cites] Cancer Res. 1989 Mar 1;49(5):1294-9 [2917359.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(17):6833-7 [2395876.001]
  • [Cites] J Cell Biol. 1991 Jan;112(1):159-68 [1986003.001]
  • [Cites] Nature. 1992 Mar 26;356(6367):344-6 [1549178.001]
  • [Cites] Semin Thromb Hemost. 1992;18(4):353-72 [1470924.001]
  • [Cites] Int J Cancer. 1993 Feb 20;53(4):651-6 [8436439.001]
  • [Cites] J Cell Biol. 1994 Apr;125(2):437-46 [8163559.001]
  • [Cites] J Invest Dermatol. 1994 Jun;102(6):987-91 [8006466.001]
  • [Cites] Genes Dev. 1994 Jun 1;8(11):1311-23 [7926732.001]
  • [Cites] Neuron. 1995 Aug;15(2):333-43 [7544141.001]
  • [Cites] Biochim Biophys Acta. 1996 Jun 7;1287(2-3):67-71 [8672529.001]
  • [Cites] Cell Growth Differ. 1996 May;7(5):663-78 [8732676.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 1996 Apr;54(4):247-59 [8804121.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 1996 Oct;55(4):261-8 [8951995.001]
  • [Cites] J Biol Chem. 1997 May 16;272(20):13236-41 [9148941.001]
  • [Cites] J Cell Biol. 1998 Apr 6;141(1):267-80 [9531564.001]
  • [Cites] Mol Biol Cell. 2004 May;15(5):2375-87 [15004227.001]
  • (PMID = 15725074.001).
  • [ISSN] 1470-8728
  • [Journal-full-title] The Biochemical journal
  • [ISO-abbreviation] Biochem. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD81; 0 / Antigens, CD9; 0 / Cd81 protein, rat; 0 / Detergents; 0 / Membrane Glycoproteins; 0 / Multiprotein Complexes; 0 / Neoplasm Proteins; 0 / Ptgfrn protein, rat; 0 / Tetraspanins; 0 / Tspan8 protein, rat
  • [Other-IDs] NLM/ PMC1184542
  •  go-up   go-down


9. Sjogren MH: Thymalfasin: an immune system enhancer for the treatment of liver disease. J Gastroenterol Hepatol; 2004 Dec;19(12):S69-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thymalfasin (thymosin-alpha 1) is an immunomodulating agent able to enhance the Thl immune response.
  • Thymalfasin is responsible for reconstitution of immune function when thymic tissue is given back to thymectomized animals.
  • In addition, thymalfasin has been shown to have efficacy in multiple experimental models of immune dysfunction, mainly, infectious diseases such as hepatitis (woodchuck) and influenza (mouse), and cancer such as melanoma (mouse) and colorectal carcinoma (rat) where thymalfasin has shown antitumor effects.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Liver Diseases / drug therapy. Thymosin / analogs & derivatives. Thymosin / therapeutic use
  • [MeSH-minor] Humans. Virus Diseases / drug therapy


10. Princivalle M, Broqua P, White R, Meyer J, Mayer G, Elliott L, Bjarnason K, Haigh R, Yea C: Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist. J Pharmacol Exp Ther; 2007 Mar;320(3):1113-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
  • One of the few animal models of prostate adenocarcinoma is the Dunning R-3327H rat carcinoma transplanted into Copenhagen rats.
  • We report in this study that degarelix produces a fast and sustained suppression of the pituitary gonadal axis in rats and a similar inhibition of tumor growth compared with surgical castration in the Dunning R-3327H rat carcinoma model.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gonadotropin-Releasing Hormone / antagonists & inhibitors. Oligopeptides / therapeutic use. Prostatic Neoplasms / drug therapy. Testosterone / blood
  • [MeSH-minor] Animals. Castration. Leuprolide / administration & dosage. Leuprolide / pharmacology. Leuprolide / therapeutic use. Male. Neoplasm Transplantation. Organ Size / drug effects. Rats. Rats, Inbred Strains. Testis / drug effects. Testis / pathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. LEUPROLIDE .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17179469.001).
  • [ISSN] 0022-3565
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Oligopeptides; 0 / acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide; 33515-09-2 / Gonadotropin-Releasing Hormone; 3XMK78S47O / Testosterone; EFY6W0M8TG / Leuprolide
  •  go-up   go-down


11. Takeuchi H, Kojima H, Yamamoto H, Kawashima Y: Passive targeting of doxorubicin with polymer coated liposomes in tumor bearing rats. Biol Pharm Bull; 2001 Jul;24(7):795-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to reveal the effectiveness of the polymer coated liposomes as a carrier of the anticancer drug doxorubicin in intravenous administration.
  • The polymer coating effects on the tumor accumulation of the drug encapsulated in the liposomes were evaluated in Walker rat carcinoma 256 cell bearing rats.
  • The doxorubicin-loaded liposomes coated with PVA-R and HPMC-R showed higher drug accumulation into the tumor site by prolonging the systemic circulation in tumor-bearing rats.
  • The targeting efficiency of the polymer coated liposomes calculated with the total and tumorous clearance of the drug was ca.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacokinetics. Carcinoma 256, Walker / metabolism. Doxorubicin / pharmacokinetics. Lactose / analogs & derivatives. Methylcellulose / analogs & derivatives
  • [MeSH-minor] Animals. Area Under Curve. Drug Carriers. Liposomes. Male. Neoplasm Transplantation. Oxazines. Particle Size. Polyvinyl Alcohol. Rats. Rats, Wistar

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. Lactose .
  • Hazardous Substances Data Bank. POLYVINYL ALCOHOL .
  • Hazardous Substances Data Bank. METHYL CELLULOSE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11456120.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Drug Carriers; 0 / Liposomes; 0 / Oxazines; 80168379AG / Doxorubicin; 9002-89-5 / Polyvinyl Alcohol; 9004-67-5 / Methylcellulose; 99705-65-4 / MK 458; J2B2A4N98G / Lactose
  •  go-up   go-down


12. Sano Y, Nakashima H, Yoshioka N, Etho N, Nomiyama T, Nishiwaki Y, Takebayashi T, Oame K: Trichloroethylene liver toxicity in mouse and rat: microarray analysis reveals species differences in gene expression. Arch Toxicol; 2009 Sep;83(9):835-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trichloroethylene liver toxicity in mouse and rat: microarray analysis reveals species differences in gene expression.
  • Trichloroethylene (TCE), an industrial organic solvent found in the environment, is a known carcinogen in laboratory animals and is believed to be carcinogenic in humans.
  • Its carcinogenicity is subject to species-specific differences in biological activity, causing hepatocellular carcinoma in mouse and renal-cell carcinoma in rat.
  • Microarray analysis revealed distinct transcriptional profiles and differences in biological pathways not only species-specific, but also pulse-dose effects within each species.
  • [MeSH-major] Carcinogens / pharmacology. Gene Expression / drug effects. Liver / drug effects. Microarray Analysis / methods. Solvents / pharmacology. Trichloroethylene / pharmacology
  • [MeSH-minor] Animals. Carcinoma, Hepatocellular / chemically induced. Carcinoma, Hepatocellular / pathology. Immunohistochemistry. Liver Neoplasms, Experimental / chemically induced. Liver Neoplasms, Experimental / pathology. Male. Mice. Organ Size / drug effects. Rats. Rats, Sprague-Dawley. Species Specificity

  • Hazardous Substances Data Bank. Trichloroethylene .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19448997.001).
  • [ISSN] 1432-0738
  • [Journal-full-title] Archives of toxicology
  • [ISO-abbreviation] Arch. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Solvents; 290YE8AR51 / Trichloroethylene
  •  go-up   go-down


13. Maliakal PP, Coville PF, Wanwimolruk S: Decreased hepatic drug metabolising enzyme activity in rats with nitrosamine-induced tumours. Drug Metabol Drug Interact; 2002;19(1):13-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased hepatic drug metabolising enzyme activity in rats with nitrosamine-induced tumours.
  • N-Methyl N-benzyl nitrosamine (MBNA), which requires P450-dependant activation to be mutagenic, has been shown to produce squamous cell carcinoma of rat oesophagus.
  • Alteration of the activities of drug metabolising enzymes in rats with chemically induced tumours could be an important factor in determining resistance or susceptibility to xenobiotics and antitumour drugs.
  • [MeSH-major] Carcinogens / pharmacology. Carcinoma, Squamous Cell / enzymology. Cytochrome P-450 Enzyme System / drug effects. Esophageal Neoplasms / enzymology. Liver / drug effects. Nitrosamines / pharmacology
  • [MeSH-minor] Animals. Aryl Hydrocarbon Hydroxylases / drug effects. Aryl Hydrocarbon Hydroxylases / metabolism. Cytochrome P-450 CYP1A2 / drug effects. Cytochrome P-450 CYP1A2 / metabolism. Cytochrome P-450 CYP2D6 / metabolism. Cytochrome P-450 CYP2E1 / drug effects. Cytochrome P-450 CYP2E1 / metabolism. Cytochrome P-450 CYP3A. Enzyme Activation / drug effects. Female. Microsomes, Liver / drug effects. Microsomes, Liver / enzymology. Organ Specificity. Oxidoreductases, N-Demethylating / drug effects. Oxidoreductases, N-Demethylating / metabolism. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12222751.001).
  • [ISSN] 0792-5077
  • [Journal-full-title] Drug metabolism and drug interactions
  • [ISO-abbreviation] Drug Metabol Drug Interact
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinogens; 0 / N-methyl-N-benzylnitrosamine; 0 / Nitrosamines; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.13.- / Cytochrome P-450 CYP2E1; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / Cytochrome P-450 CYP1A2; EC 1.14.14.1 / Cytochrome P-450 CYP2D6; EC 1.14.14.1 / Cytochrome P-450 CYP3A; EC 1.5.- / Oxidoreductases, N-Demethylating
  •  go-up   go-down


14. Ajith TA, Janardhanan KK: Chemopreventive activity of a macrofungus Phellinus rimosus against N-nitrosodiethylamine induced hepatocellular carcinoma in rat. J Exp Ther Oncol; 2006;5(4):309-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemopreventive activity of a macrofungus Phellinus rimosus against N-nitrosodiethylamine induced hepatocellular carcinoma in rat.
  • Chemical substances with multiple inhibitory properties would be a welcome addition to the class of chemopreventive drugs.
  • The concentration required to inhibit 50% of Fe2+ induced lipid peroxidation in rat liver homogenate was 318 +/- 2.4 microg/ml.
  • Anticarcinogenic activity was evaluated using N-nitrosodiethylamine (NDEA) induced hepatocellular carcinoma (HCC) in rats.
  • Serum gamma glutamyl transpeptidase (GGT), glutamate oxaloacetate transaminase (GOT), glutamate pyruvate transaminase (GPT) and alkaline phosphatase (ALP) activities and lipid peroxidation level (MDA) were elevated significantly (P<0.05) in the NDEA alone treated group of animals.
  • The NDEA alone treated animals showed altered serum albumin/globulin ratio (A:G ratio), hyperfibrinogenaemia, increased hepatic glutathione S-transferase (GST) activity, glutathione-peroxidsae (GPx) activity and reduced glutathione (GSH) level compared to the extract plus NDEA treated group.
  • The extract also inhibited in vitro aniline hydroxylase (AH) activity of rat liver induced by phenobarbitone in a dose dependent manner.
  • The results, thus suggest the significant chemopreventive properties of the aqueous extract of the Phellinus rimosus against NDEA induced hepatocellular carcinoma by its antioxidant, anti-inflammatory and antimutagenic activities.
  • [MeSH-major] Anticarcinogenic Agents / pharmacology. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / prevention & control. Diethylnitrosamine / pharmacology. Fungi / metabolism. Liver Neoplasms / drug therapy. Liver Neoplasms / prevention & control
  • [MeSH-minor] Animals. Antioxidants / pharmacology. Hydroxyl Radical. Inhibitory Concentration 50. Lipid Peroxidation. Liver / metabolism. Male. Mutagens. Nitric Oxide / metabolism. Rats

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Molds.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. N-NITROSODIETHYLAMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17024971.001).
  • [ISSN] 1359-4117
  • [Journal-full-title] Journal of experimental therapeutics & oncology
  • [ISO-abbreviation] J. Exp. Ther. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antioxidants; 0 / Mutagens; 31C4KY9ESH / Nitric Oxide; 3352-57-6 / Hydroxyl Radical; 3IQ78TTX1A / Diethylnitrosamine
  •  go-up   go-down


15. Zhang X, Ren L, Hu X, Wang W, Yin H, Liu H, Zhang Y: Gene profiling of cyclosporin-enhanced transitional cell carcinoma in rat model. Transplant Proc; 2009 Dec;41(10):4369-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene profiling of cyclosporin-enhanced transitional cell carcinoma in rat model.
  • MATERIALS AND METHODS: The observation was performed in a rat model, in which transitional cell carcinoma of urinary bladder was induced with N-butyl-N-(-4-hydroxybutyl) nitrosamine.
  • [MeSH-major] Carcinoma, Transitional Cell / genetics. Cyclosporine / toxicity. Gene Expression Profiling
  • [MeSH-minor] Animals. Body Weight. Chromosome Mapping. Down-Regulation. Gene Expression Regulation / drug effects. Gene Expression Regulation / immunology. Genetic Variation. Male. Organ Size. Rats. Rats, Sprague-Dawley. Up-Regulation. Urinary Bladder / anatomy & histology. Weight Gain

  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20005401.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


16. Tybitanclova K, Macejova D, Liska J, Brtko J, Zorad S: AT1 receptor and ACE mRNA are increased in chemically induced carcinoma of rat mammary gland. Mol Cell Endocrinol; 2005 Dec 1;244(1-2):42-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AT1 receptor and ACE mRNA are increased in chemically induced carcinoma of rat mammary gland.
  • The aim of this study was to investigate the gene expression of components of the renin-angiotensin system, angiotensinogen, renin, angiotensin-converting enzyme and AT(1) receptor, in rat mammary gland and in chemically induced carcinoma of this gland.
  • Retinoids are known to inhibit cell proliferation and induce cell differentiation so they are considered as a promising chemopreventive agents.
  • The expressions in control and carcinoma tissue were investigated using RT-PCR and activity of angiotensin-converting enzyme was measured.
  • The amount of angiotensin-converting enzyme and AT(1) receptor mRNA and angiotensin-converting enzyme activity always showed a significant increase in the carcinoma tissue in comparison with the control.
  • Administration of 13-cis-retinoic acid to rats with induced mammary gland carcinoma was without significant effect on either tumour numbers or tumour burden and volume.
  • Our results demonstrate the presence of angiotensin-converting enzyme and AT(1) receptor in control and carcinoma tissue of mammary gland.
  • We assume that both proteins might play a role in development of tumour cells and vasculature.
  • [MeSH-major] Gene Expression / drug effects. Isotretinoin / pharmacology. Mammary Glands, Animal / metabolism. Mammary Neoplasms, Experimental / metabolism. Peptidyl-Dipeptidase A / metabolism. Receptor, Angiotensin, Type 1 / metabolism
  • [MeSH-minor] Angiotensinogen / genetics. Angiotensinogen / metabolism. Animals. Female. Methylnitrosourea. RNA, Messenger / metabolism. Rats. Rats, Sprague-Dawley. Renin / genetics. Renin / metabolism. Renin-Angiotensin System / genetics. Renin-Angiotensin System / physiology. Reverse Transcriptase Polymerase Chain Reaction

  • Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .
  • Hazardous Substances Data Bank. N-NITROSO-N-METHYLUREA .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16225983.001).
  • [ISSN] 0303-7207
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptor, Angiotensin, Type 1; 11002-13-4 / Angiotensinogen; 684-93-5 / Methylnitrosourea; EC 3.4.15.1 / Peptidyl-Dipeptidase A; EC 3.4.23.15 / Renin; EH28UP18IF / Isotretinoin
  •  go-up   go-down


17. Marchetti S, Chazal M, Dubreuil A, Fischel JL, Etienne MC, Milano G: Impact of thymidine phosphorylase surexpression on fluoropyrimidine activity and on tumour angiogenesis. Br J Cancer; 2001 Aug 3;85(3):439-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the study was to investigate more thoroughly these potential physiological and pharmacological roles of TP.
  • A rat carcinoma cell line (PROb) was transfected with TP/PD-ECGF in order to study the effect of the overexpression of this enzyme (1) on the sensitivity of cells to 5'DFUR and 5FU in vitro and (2) on tumour growth in vivo by using a syngenic tumour model in the BDIX rat (hepatic tumours, sub-cutaneous tumours).
  • [MeSH-minor] Animals. Drug Resistance, Neoplasm. Formazans. Neoplasm Transplantation. Pentosyltransferases / metabolism. Pyrimidine Phosphorylases. Rats. Tetrazolium Salts. Transfection. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / enzymology

  • Hazardous Substances Data Bank. FLOXURIDINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Cancer Research Campaign.
  • [Cites] Cancer Res. 1995 Apr 15;55(8):1687-90 [7536129.001]
  • [Cites] J Pathol. 1995 Jun;176(2):183-90 [7636628.001]
  • [Cites] J Biol Chem. 1995 Aug 11;270(32):19073-7 [7642571.001]
  • [Cites] Br J Cancer. 1995 Sep;72(3):669-75 [7669579.001]
  • [Cites] Br J Cancer. 1996 Feb;73(3):275-80 [8562330.001]
  • [Cites] Jpn J Cancer Res. 1996 Mar;87(3):288-95 [8613432.001]
  • [Cites] Eur J Cancer. 1996 Jun;32A(7):1227-32 [8758258.001]
  • [Cites] J Natl Cancer Inst. 1996 Aug 21;88(16):1091-2 [8757181.001]
  • [Cites] J Natl Cancer Inst. 1996 Aug 21;88(16):1110-7 [8757190.001]
  • [Cites] Br J Cancer. 1997;75(4):506-11 [9052401.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2570-8 [9215827.001]
  • [Cites] Int J Cancer. 1997 Oct 21;74(5):545-50 [9355979.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):685-90 [9485021.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1225-32 [9529012.001]
  • [Cites] Clin Cancer Res. 1998 Apr;4(4):1013-9 [9563897.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1795-802 [9586893.001]
  • [Cites] Biochem J. 1998 Aug 15;334 ( Pt 1):1-8 [9693094.001]
  • [Cites] Clin Cancer Res. 1997 Jun;3(6):973-6 [9815773.001]
  • [Cites] Clin Exp Metastasis. 1998 Oct;16(7):665-72 [9932613.001]
  • [Cites] Int J Cancer. 1999 Jan 29;80(3):465-70 [9935191.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1911-6 [10213500.001]
  • [Cites] J Biol Chem. 1964 Aug;239:2618-21 [14235544.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1529-35 [10778986.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6298-302 [11103787.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Cancer Res. 1978 Jun;38(6):1739-44 [647684.001]
  • [Cites] Int J Cancer. 1985 Aug 15;36(2):273-9 [4018914.001]
  • [Cites] Cancer Res. 1987 Feb 15;47(4):936-42 [3802100.001]
  • [Cites] Mutat Res. 1988 Jul-Aug;200(1-2):99-116 [3393166.001]
  • [Cites] Nature. 1989 Apr 13;338(6216):557-62 [2467210.001]
  • [Cites] Biochemistry. 1992 Dec 8;31(48):12141-6 [1457409.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;32(5):333-8 [8339382.001]
  • [Cites] Cancer Res. 1995 Feb 1;55(3):510-3 [7530595.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):998-1002 [7532308.001]
  • (PMID = 11487278.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Formazans; 0 / Tetrazolium Salts; 039LU44I5M / Floxuridine; 23305-68-2 / MTT formazan; EC 2.4.2.- / Pentosyltransferases; EC 2.4.2.- / Pyrimidine Phosphorylases; EC 2.4.2.4 / Thymidine Phosphorylase; U3P01618RT / Fluorouracil; V1JK16Y2JP / doxifluridine
  • [Other-IDs] NLM/ PMC2364074
  •  go-up   go-down


18. Telgenhoff DJ, Aggarwal SK: Mechanisms of actio of poly-plat, a novel platinum antineoplastic agent. Anticancer Res; 2002 Jul-Aug;22(4):2167-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanisms of actio of poly-plat, a novel platinum antineoplastic agent.
  • Action of Cisplatin (cis-dichlorodiammine platinum II) and Poly-Plat [poly-[(trans-1,2-diaminocyclohexane) pla-tinum]-carboxyamylose] on tumor cells was examined using human fibrosarcoma (HT1080) and Walker rat carcinoma (WRC-256) in culture.
  • Apoptotic assays were used to determine the cytotoxic effects of drugs and macrophage supernatants on tumor cells.
  • [MeSH-major] Antineoplastic Agents / toxicity. Cisplatin / toxicity. Fibrosarcoma / pathology. Organoplatinum Compounds / toxicity
  • [MeSH-minor] Apoptosis / drug effects. Cell Survival / drug effects. Humans. Interleukin-2 / analysis. Macrophages / drug effects. Macrophages / immunology. Mitosis / drug effects. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12174899.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-2; 0 / Organoplatinum Compounds; 0 / poly(trans-1,2-diaminocyclohexane)platinum-carboxyamylose; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


19. Labaree DC, Reynolds TY, Hochberg RB: Estradiol-16alpha-carboxylic acid esters as locally active estrogens. J Med Chem; 2001 May 24;44(11):1802-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We synthesized a series of 16alpha-carboxylic acid substituted steroids and their esters and tested their action in several assays of estrogenic action, including estrogen receptor (ER) binding, estrogenic potency in Ishikawa cells (human endometrial carcinoma), rat uterine weight (systemic action), and mouse vaginal reductases (local action).
  • All of the estradiol substituted carboxylic acids (formic, acetic and propionic acids) were devoid of estrogenic action.
  • This decrease correlated well with the increased rate of esterase hydrolysis of longer esters as determined in incubations with rat hepatic microsomes.
  • [MeSH-minor] Alkaline Phosphatase / biosynthesis. Animals. Binding, Competitive. Enzyme Induction. Esters / chemistry. Esters / pharmacology. Estrogen Receptor alpha. Estrogen Receptor beta. Female. Humans. In Vitro Techniques. Mice. Microsomes, Liver / enzymology. Organ Size. Ovariectomy. Oxidoreductases / biosynthesis. Rats. Rats, Sprague-Dawley. Receptors, Estrogen / metabolism. Structure-Activity Relationship. Tumor Cells, Cultured. Uterus / anatomy & histology. Uterus / drug effects. Uterus / metabolism. Vagina / enzymology

  • Hazardous Substances Data Bank. ESTRADIOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11356114.001).
  • [ISSN] 0022-2623
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Esters; 0 / Estradiol Congeners; 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / Receptors, Estrogen; 4TI98Z838E / Estradiol; EC 1.- / Oxidoreductases; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


20. Arum CJ, Kodama Y, Rolim N, Widerøe M, Anderssen E, Viset T, Otterlei M, Lundgren S, Chen D, Zhao CM: A rat model of intravesical delivery of small interfering RNA for studying urinary carcinoma. World J Urol; 2010 Aug;28(4):479-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rat model of intravesical delivery of small interfering RNA for studying urinary carcinoma.
  • The aims of the present study were (1) to establish rat models for in vivo delivery of siRNA to bladder cancer, and (2) to identify potential targets for siRNA.
  • METHODS: The rat models of human urinary carcinoma and rat urinary carcinoma cell line (AY-27) were induced by tobacco-related chemical carcinogens, either N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide (FANFT) or N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN).
  • Bioinformatics analysis revealed a list of concordantly highly expressed genes, possible siRNA targets, in the animal models as well as human urinary carcinoma.
  • CONCLUSION: The methodology and data presented in the present study provide a number of opportunities for basic research on urinary carcinogenesis and for translational research on evaluation of siRNA therapeutic strategies for urinary carcinoma in the native organ, where hormonal, neural and immunological processes more closely resemble the clinical situation.
  • [MeSH-minor] Administration, Intravesical. Animals. Biopsy. Cell Line, Tumor. Disease Models, Animal. Female. Fluorescent Dyes. Rats. Rats, Inbred F344

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nanomedicine. 2009 Mar;5(1):8-20 [18640078.001]
  • [Cites] Nat Med. 2005 Mar;11(3):263-70 [15723075.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):806-11 [9486653.001]
  • [Cites] J Cell Physiol. 2009 Aug;220(2):285-91 [19391103.001]
  • [Cites] Br J Cancer. 1999 Oct;81(4):638-46 [10574249.001]
  • [Cites] J Urol. 2009 Aug;182(2):741-8 [19539325.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):978-85 [15761500.001]
  • [Cites] Neoplasia. 2007 Mar;9(3):207-21 [17401461.001]
  • [Cites] Neoplasia. 2008 Aug;10(8):838-46 [18670642.001]
  • [Cites] J Mol Endocrinol. 2004 Dec;33(3):545-57 [15591019.001]
  • [Cites] Oligonucleotides. 2009 Jun;19(2):89-102 [19441890.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4017-20 [12874000.001]
  • [Cites] Cytometry. 1984 Sep;5(5):447-53 [6489059.001]
  • [Cites] Adv Drug Deliv Rev. 2009 Aug 10;61(10):850-62 [19422869.001]
  • [Cites] Urology. 2010 Mar;75(3):742-9 [19647301.001]
  • [Cites] World J Urol. 2009 Jun;27(3):353-61 [19214530.001]
  • [Cites] J Clin Invest. 2007 Dec;117(12):3623-32 [18060020.001]
  • [Cites] Mol Ther. 2009 Jul;17(7):1225-33 [19401674.001]
  • [Cites] J Urol. 2008 Jan;179(1):53-6 [17997439.001]
  • [Cites] Nat Biotechnol. 2005 Apr;23(4):457-62 [15778705.001]
  • [Cites] Environ Health Perspect. 1983 Mar;49:217-22 [6832095.001]
  • [Cites] J Mol Biol. 2005 May 20;348(5):1079-90 [15854645.001]
  • [Cites] Cancer Res. 1977 Aug;37(8 Pt 2):2813-6 [326392.001]
  • [Cites] J Clin Invest. 2009 May;119(5):1216-29 [19381019.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2008 Sep;(218):12-20 [19054893.001]
  • [Cites] Angew Chem Int Ed Engl. 2007;46(37):6966-84 [17722137.001]
  • (PMID = 20376453.001).
  • [ISSN] 1433-8726
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Fluorescent Dyes; 0 / RNA, Small Interfering
  •  go-up   go-down


21. Losa M, Mazza E, Terreni MR, McCormack A, Gill AJ, Motta M, Cangi MG, Talarico A, Mortini P, Reni M: Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. Eur J Endocrinol; 2010 Dec;163(6):843-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The prognosis of either pituitary carcinoma or aggressive pituitary adenoma resistant to standard therapies is poor.
  • We assessed the efficacy of treatment with temozolomide, an oral second-generation alkylating agent, in a consecutive series of six patients with aggressive pituitary adenomas.
  • DESIGN: This was a 1-year prospective study of temozolomide therapy in six consecutive patients with pituitary carcinoma (one case) or atypical pituitary adenoma (five cases) resistant to standard therapies.
  • Two patients stopped the drug after 3 and 6 months respectively because of the progression of disease.
  • Immunohistochemistry for O(6)-methylguanine-DNA methyltransferase (MGMT) in tumor sample showed a partial association with treatment response.
  • CONCLUSIONS: Temozolomide treatment has a wide range of efficacy in patients with pituitary carcinoma or locally aggressive pituitary adenoma.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20870708.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


22. Levine L: Proteasome inhibitors: their effects on arachidonic acid release from cells in culture and arachidonic acid metabolism in rat liver cells. BMC Pharmacol; 2004 Aug 5;4:15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteasome inhibitors: their effects on arachidonic acid release from cells in culture and arachidonic acid metabolism in rat liver cells.
  • BACKGROUND: I have postulated that arachidonic acid release from rat liver cells is associated with cancer chemoprevention.
  • Since it has been reported that inhibition of proteasome activities may prevent cancer, the effects of proteasome inhibitors on arachidonic acid release from cells and on prostaglandin I2 production in rat liver cells were studied.
  • RESULTS: The proteasome inhibitors, epoxomicin, lactacystin and carbobenzoxy-leucyl-leucyl-leucinal, stimulate the release of arachidonic acid from rat glial, human colon carcinoma, human breast carcinoma and the rat liver cells.
  • They also stimulate basal and induced prostacycin production in the rat liver cells.
  • The stimulated arachidonic acid release and basal prostaglandin I2 production in rat liver cells is inhibited by actinomycin D.
  • CONCLUSIONS: Stimulation of arachidonic acid release and arachidonic acid metabolism may be associated with some of the biologic effects observed after proteasome inhibition, e.g. prevention of tumor growth, induction of apoptosis, stimulation of bone formation.
  • [MeSH-major] Acetylcysteine / analogs & derivatives. Arachidonic Acid / metabolism. Liver / drug effects. Liver / metabolism. Proteasome Inhibitors
  • [MeSH-minor] Animals. Breast Neoplasms / metabolism. Cell Line. Cell Line, Tumor. HT29 Cells / drug effects. HT29 Cells / metabolism. Humans. Leupeptins / pharmacology. Neuroglia / drug effects. Neuroglia / metabolism. Oligopeptides / pharmacology. Rats

  • Hazardous Substances Data Bank. N-ACETYLCYSTEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Biochem Biophys. 2000 Feb 15;374(2):325-33 [10666314.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2000 Dec;63(6):371-5 [11133174.001]
  • [Cites] Endocr Rev. 1999 Jun;20(3):253-78 [10368771.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10403-8 [10468620.001]
  • [Cites] J Clin Invest. 2001 Jun;107(11):1339-45 [11390413.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2001 Jul;65(1):31-5 [11487305.001]
  • [Cites] Chem Biol. 2001 Aug;8(8):739-58 [11514224.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2002 Dec;67(6):453-9 [12468267.001]
  • [Cites] Trends Pharmacol Sci. 2003 Feb;24(2):96-102 [12559775.001]
  • [Cites] Drug Discov Today. 2003 Apr 1;8(7):307-15 [12654543.001]
  • [Cites] FASEB J. 2003 May;17(8):800-2 [12724337.001]
  • [Cites] J Clin Invest. 2003 Jun;111(11):1771-82 [12782679.001]
  • [Cites] J Natl Cancer Inst. 2003 Jun 18;95(12):844-6 [12813163.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2597-8 [12826633.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2003 Aug-Sep;69(2-3):87-97 [12895591.001]
  • [Cites] Drug Discov Today. 2003 Aug 1;8(15):710-6 [12927514.001]
  • [Cites] Annu Rev Biophys Biomol Struct. 2003;32:257-83 [12543707.001]
  • [Cites] BMC Cancer. 2003 Sep 19;3:24 [14498998.001]
  • [Cites] BMC Cancer. 2004 Aug 13;4:49 [15310397.001]
  • [Cites] J Pharmacol Exp Ther. 1984 Nov;231(2):230-5 [6436471.001]
  • [Cites] Biochem J. 1989 Apr 15;259(2):315-24 [2655580.001]
  • [Cites] J Antibiot (Tokyo). 1992 Nov;45(11):1746-52 [1468981.001]
  • [Cites] Cell. 1995 Jun 16;81(6):957-66 [7781071.001]
  • [Cites] Biochem J. 1996 Apr 1;315 ( Pt 1):85-9 [8670136.001]
  • [Cites] Biochem Biophys Res Commun. 1997 May 29;234(3):729-32 [9175783.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6629-34 [9192616.001]
  • [Cites] Nat Genet. 1997 Sep;17(1):88-91 [9288104.001]
  • [Cites] J Biol Chem. 1997 Nov 21;272(47):29899-903 [9368065.001]
  • [Cites] Oncogene. 1998 Oct 15;17(15):2009-12 [9788445.001]
  • [Cites] Cell Signal. 1998 Oct;10(9):653-9 [9794247.001]
  • (PMID = 15296516.001).
  • [ISSN] 1471-2210
  • [Journal-full-title] BMC pharmacology
  • [ISO-abbreviation] BMC Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Leupeptins; 0 / Oligopeptides; 0 / Proteasome Inhibitors; 133343-34-7 / lactacystin; 133407-82-6 / benzyloxycarbonylleucyl-leucyl-leucine aldehyde; 134381-21-8 / epoxomicin; 27YG812J1I / Arachidonic Acid; WYQ7N0BPYC / Acetylcysteine
  • [Other-IDs] NLM/ PMC514535
  •  go-up   go-down


23. Abramjuk C, Lein M, Rothaug W, Krell HW, Loening SA, Jung K: Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine and etoposide on the prostate carcinoma in the rat Dunning orthotopic tumor model. Cancer Chemother Pharmacol; 2007 Feb;59(2):275-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine and etoposide on the prostate carcinoma in the rat Dunning orthotopic tumor model.
  • We hypothesized that the inhibitor effect of Ro 28-2653 on the tumor growth could be improved by combination with chemotherapeutic drugs and examined therefore the effect of Ro 28-2653 alone and in combination with etoposide or estramustine in the MatLyLu Dunning R-3327 rat tumor model characteristic for the androgen-independent prostate cancer (PCa).
  • METHODS: In vitro effects were estimated measuring the proliferation of MatLyLu cells incubated with the three agents alone or in combination using the XTT test.
  • The in vivo effects of the agents alone or in combination were examined by measuring the tumor weight 18 days after tumor cell injection.
  • CONCLUSIONS: The inhibitory effect of the MMP inhibitor Ro 28-2653 on the tumor growth in the Dunning PCa model is enhanced by the standard chemotherapeutic drug etoposide.
  • A combined application of both agents could be considered as potential tool to improve the therapy of patients with advanced PCa after failure of hormonal treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Animals. Body Weight / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Disease Models, Animal. Drug Resistance, Neoplasm. Drug Screening Assays, Antitumor / methods. Drug Synergism. Estramustine / administration & dosage. Etoposide / administration & dosage. Humans. Injections, Intraperitoneal. Male. Neoplasm Invasiveness / prevention & control. Neoplasm Transplantation. Piperazines / administration & dosage. Pyrimidines / administration & dosage. Rats. Time Factors. Tissue Inhibitor of Metalloproteinases / administration & dosage

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16758188.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Piperazines; 0 / Pyrimidines; 0 / Ro 28-2653; 0 / Tissue Inhibitor of Metalloproteinases; 35LT29625A / Estramustine; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


24. Yu S, Peng HD, Ju DW, Wei PK, Xu L, Lao LX, Li J: Mechanisms of treatment of cancer pain with a topical Chinese herbal formula in rats. Chin Med J (Engl); 2009 Sep 5;122(17):2027-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pain has a substantial impact on patients' activities and overall quality of life, but current conventional drugs have debilitating side effects, including gastrointestinal disorders.
  • The aim of this study was to determine the analgesic effects and explore the mechanisms of XTTL gel in a rat model of bone cancer pain.
  • METHODS: The rat model of bone cancer pain was established by inoculating Walker-256 rat carcinoma cells directly into the right tibial medullary cavity of Wistar rats.
  • (1) sham bone cancer control (sham group): vehicle (PBS) inoculation without carcinoma cells plus topical administration of blank gel;.
  • Outcomes were assessed 21 days after inoculation by mechanical allodynia, histological staining, and by measuring concentrations of type I collagen carboxy-terminal telopeptide (ICTP) and bone-specific alkaline phosphatase (BAP) in serum.
  • [MeSH-major] Bone Neoplasms / complications. Drugs, Chinese Herbal / therapeutic use. Pain / drug therapy. Pain / etiology
  • [MeSH-minor] Alkaline Phosphatase / metabolism. Animals. Body Weight. Cell Line, Tumor. Collagen Type I. Female. Peptide Fragments / blood. Peptides. Procollagen / blood. Random Allocation. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19781391.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Collagen Type I; 0 / Drugs, Chinese Herbal; 0 / Peptide Fragments; 0 / Peptides; 0 / Procollagen; 0 / collagen type I trimeric cross-linked peptide; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


25. Shinozaki K, Ebert O, Kournioti C, Tai YS, Woo SL: Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus. Mol Ther; 2004 Mar;9(3):368-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus.
  • Hepatocellular carcinoma (HCC) is a lethal malignancy with poor prognosis and few effective treatments, as well as ever-increasing frequencies in the Western world.
  • Viruses that replicate selectively in cancer cells hold considerable promise as novel therapeutic agents for the treatment of malignancy.
  • The aim of this study was to evaluate the potential of VSV, administered via the hepatic artery, as an effective and safe therapeutic agent for treating "multifocal" HCC in the rat liver.
  • Finally, survival of vector-treated rats was substantially prolonged over that of animals in the control treatment group (p < 0.028).
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Genetic Therapy / methods. Hepatic Artery / metabolism. Infusions, Intra-Arterial. Liver / metabolism. Liver Neoplasms / therapy. Vesicular stomatitis Indiana virus / genetics
  • [MeSH-minor] Animals. Cell Line, Tumor. Cytokines / biosynthesis. Galactosides / metabolism. Genetic Vectors. Humans. Immunohistochemistry. Indoles / metabolism. Inflammation. Kinetics. Male. Rats. Time Factors. beta-Galactosidase / genetics

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15006603.001).
  • [ISSN] 1525-0016
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA100830
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Galactosides; 0 / Indoles; EC 3.2.1.23 / beta-Galactosidase; V595OG374W / 5-bromo-4-chloro-3-indolyl beta-galactoside
  •  go-up   go-down


26. Arulkumaran S, Ramprasath VR, Shanthi P, Sachdanandam P: Restorative effect of Kalpaamruthaa, an indigenous preparation, on oxidative damage in mammary gland mitochondrial fraction in experimental mammary carcinoma. Mol Cell Biochem; 2006 Oct;291(1-2):77-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Restorative effect of Kalpaamruthaa, an indigenous preparation, on oxidative damage in mammary gland mitochondrial fraction in experimental mammary carcinoma.
  • Recent studies have shown that Semecarpus anacardium Linn nut milk extract (SA), a promising antioxidant and anticancer drug, exerts its anticancer effect through reducing or quenching reactive oxygen species under different conditions.
  • The present study examined whether Phyllanthus emblica Linn fruit, rich in vitamin C content synergistically in combination can enhance both the antioxidant and anticancer activity of S. anacardium nut milk extract in 7, 12-dimethyl benz[a]anthracene (DMBA)-induced experimental mammary carcinoma in rat model.
  • Three groups were administered DMBA (25mg/rat, orally) dissolved in olive oil to induce mammary carcinoma.
  • A vehicle treated control and drug control groups were also included.
  • [MeSH-major] Mammary Glands, Animal / pathology. Mammary Neoplasms, Experimental / drug therapy. Mitochondria / drug effects. Oxidative Stress / drug effects. Plant Extracts / pharmacology. Plant Extracts / therapeutic use. Semecarpus / metabolism
  • [MeSH-minor] Animals. Antineoplastic Agents, Phytogenic / pharmacology. Antineoplastic Agents, Phytogenic / therapeutic use. Antioxidants / metabolism. Female. Lipid Peroxidation / drug effects. Phytotherapy. Rats. Rats, Sprague-Dawley

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Free Radic Biol Med. 2004 Aug 1;37(3):287-303 [15223063.001]
  • [Cites] Crit Rev Food Sci Nutr. 2004;44(4):253-73 [15462129.001]
  • [Cites] Pharmacol Res. 1997 Sep;36(3):187-92 [9367662.001]
  • [Cites] J Pharm Pharmacol. 2003 Sep;55(9):1283-90 [14604472.001]
  • [Cites] Am Pharm. 1994 Sep;NS34(9):26-35 [7977023.001]
  • [Cites] Biochem Soc Trans. 2003 Dec;31(Pt 6):1441-4 [14641084.001]
  • [Cites] Indian J Exp Biol. 1999 Jul;37(7):676-80 [10522157.001]
  • [Cites] Biochem J. 1952 Oct;52(2):185-96 [13018205.001]
  • [Cites] Science. 1973 Feb 9;179(4073):588-90 [4686466.001]
  • [Cites] Tumour Biol. 1988;9(5):241-8 [2973647.001]
  • [Cites] Indian J Exp Biol. 2000 Dec;38(12):1177-82 [11411037.001]
  • [Cites] Cancer Res. 1975 Aug;35(8):2061-7 [167945.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18 Suppl):106S-111S [11560984.001]
  • [Cites] J Biol Chem. 1948 Jul;174(3):961-77 [18871256.001]
  • [Cites] Prog Exp Tumor Res. 1978;22:190-274 [149996.001]
  • [Cites] J Photochem Photobiol B. 1990 Apr 15;5(2):133-50 [2111395.001]
  • [Cites] Diabetes. 1997 Sep;46 Suppl 2:S14-8 [9285493.001]
  • [Cites] Anticancer Res. 1999 Sep-Oct;19(5B):4177-86 [10628372.001]
  • [Cites] Methods Enzymol. 1984;105:138-47 [6727662.001]
  • [Cites] Eur J Biochem. 1974 Sep 16;47(3):469-74 [4215654.001]
  • [Cites] Pathol Biol (Paris). 1996 Jan;44(1):25-8 [8734296.001]
  • [Cites] Life Sci. 2004 Mar 12;74(17):2157-84 [14969719.001]
  • [Cites] Photochem Photobiol. 1988 Aug;48(2):195-9 [3222330.001]
  • [Cites] Anal Biochem. 1972 Jun;47(2):389-94 [4556490.001]
  • [Cites] Free Radic Biol Med. 2004 Apr 1;36(7):838-49 [15019969.001]
  • [Cites] J Nat Prod. 2001 Dec;64(12 ):1527-32 [11754604.001]
  • [Cites] Pharmacol Rev. 2002 Mar;54(1):101-27 [11870261.001]
  • [Cites] Biochem J. 1997 May 15;324 ( Pt 1):1-18 [9164834.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] J Nutr. 2004 Jun;134(6):1459-66 [15173412.001]
  • [Cites] Biochem Biophys Res Commun. 1974 Feb 4;56(3):836-42 [4151195.001]
  • [Cites] Free Radic Biol Med. 2004 Mar 15;36(6):718-44 [14990352.001]
  • [Cites] Methods Enzymol. 1979;62:3-11 [440112.001]
  • [Cites] Biochim Biophys Acta. 1979 Jan 4;582(1):67-78 [760819.001]
  • [Cites] J Ethnopharmacol. 2001 May;75(2-3):65-9 [11297836.001]
  • [Cites] Braz J Med Biol Res. 2004 Jul;37(7):1029-34 [15264010.001]
  • (PMID = 16953336.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Antioxidants; 0 / Plant Extracts
  •  go-up   go-down


27. Mertins SD, Myers TG, Holbeck SL, Medina-Perez W, Wang E, Kohlhagen G, Pommier Y, Bates SE: In vitro evaluation of dimethane sulfonate analogues with potential alkylating activity and selective renal cell carcinoma cytotoxicity. Mol Cancer Ther; 2004 Jul;3(7):849-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro evaluation of dimethane sulfonate analogues with potential alkylating activity and selective renal cell carcinoma cytotoxicity.
  • A COMPARE analysis with the National Cancer Institute Anticancer Drug Screen standard agent database found significant correlations between the IC50 of the test compounds and the IC50 of alkylating agents (e.g., r = 0.68, P < 0.00001 for chlorambucil).
  • In this report, we examined whether these compounds had activities similar to those of conventional alkylating agents.
  • In cytotoxicity studies, chlorambucil-resistant Walker rat carcinoma cells were 4- to 11-fold cross-resistant to the test compounds compared with 14-fold resistant to chlorambucil.
  • To determine effects on cell cycle progression, renal cell carcinoma (RCC) line 109 was labeled with bromodeoxyuridine prior to drug treatment.
  • Complete cell cycle arrest occurred in cells treated with an IC90 dose of NSC 268965. p53 protein levels increased as much as 5.7-fold in RCC line 109 and as much as 20.4-fold in breast cancer line MCF-7 following an 18-hour drug exposure.
  • Thus, the dimethane sulfonate analogues have properties expected of some alkylating agents but, unlike conventional alkylating agents, appear to possess activity against RCC.
  • [MeSH-major] Alkylating Agents / chemistry. Alkylating Agents / toxicity. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy. Mesylates / chemistry. Mesylates / toxicity
  • [MeSH-minor] Animals. Bromodeoxyuridine / analysis. Busulfan / analogs & derivatives. Carmustine / analogs & derivatives. Cell Cycle / drug effects. DNA Damage. Drug Evaluation, Preclinical. Drug Resistance, Neoplasm / drug effects. Humans. Inhibitory Concentration 50. Rats. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Protein p53 / metabolism. Yeasts / drug effects

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15252146.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Mesylates; 0 / Tumor Suppressor Protein p53; G1LN9045DK / Busulfan; G34N38R2N1 / Bromodeoxyuridine; U68WG3173Y / Carmustine
  •  go-up   go-down


28. Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L, Laezza C, Portella G, Bifulco M, Di Marzo V: Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther; 2006 Sep;318(3):1375-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma.
  • Both cannabidiol and the cannabidiol-rich extract inhibited the growth of xenograft tumors obtained by s.c. injection into athymic mice of human MDA-MB-231 breast carcinoma or rat v-K-ras-transformed thyroid epithelial cells and reduced lung metastases deriving from intrapaw injection of MDA-MB-231 cells.
  • At least for MDA-MB-231 cells, however, our experiments indicate that cannabidiol effect is due to its capability of inducing apoptosis via: direct or indirect activation of cannabinoid CB(2) and vanilloid transient receptor potential vanilloid type-1 receptors and cannabinoid/vanilloid receptor-independent elevation of intracellular Ca(2+) and reactive oxygen species.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Breast Neoplasms / drug therapy. Cannabidiol / pharmacology. Cannabinoids / pharmacology
  • [MeSH-minor] Animals. Calcium / metabolism. Cell Line, Tumor. Cell Proliferation / drug effects. Humans. Male. Mice. Mice, Inbred BALB C. Oxidative Stress. Receptor, Cannabinoid, CB1 / physiology. Receptor, Cannabinoid, CB2 / physiology. TRPV Cation Channels / physiology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16728591.001).
  • [ISSN] 0022-3565
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Cannabinoids; 0 / Receptor, Cannabinoid, CB1; 0 / Receptor, Cannabinoid, CB2; 0 / TRPV Cation Channels; 0 / TRPV1 protein, human; 19GBJ60SN5 / Cannabidiol; SY7Q814VUP / Calcium
  •  go-up   go-down


29. Krupka TM, Weinberg BD, Ziats NP, Haaga JR, Exner AA: Injectable polymer depot combined with radiofrequency ablation for treatment of experimental carcinoma in rat. Invest Radiol; 2006 Dec;41(12):890-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Injectable polymer depot combined with radiofrequency ablation for treatment of experimental carcinoma in rat.
  • OBJECTIVE: The purpose of this study was to investigate whether an intralesional chemotherapy depot with or without a chemosensitizer could improve the efficacy of radiofrequency (RF) ablation in treatment of experimental carcinoma in rats.
  • MATERIALS AND METHODS: Eighteen BD-IX rats were inoculated with bilateral subcutaneous tumors via injection of DHD/K12TRb rat colorectal carcinoma cells in suspension.
  • Four weeks after inoculation, one tumor in each rat was treated with RF ablation at 80 degrees C for 2 minutes and the other with RF ablation followed by intralesional chemotherapy with carboplatin.
  • The drug was administered via 2 different in situ-forming poly(D,L-lactide-coglycolide) (PLGA) depot formulations either with or without a chemosensitizer.
  • [MeSH-major] Carcinoma / therapy. Catheter Ablation. Colorectal Neoplasms / therapy. Poloxalene / administration & dosage
  • [MeSH-minor] Animals. Antineoplastic Agents / administration & dosage. Carboplatin / administration & dosage. Cell Line, Tumor. Combined Modality Therapy. Delayed-Action Preparations / administration & dosage. Female. Injections, Intralesional. Male. Neoplasm Transplantation. Rats. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. POLOXALENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17099428.001).
  • [ISSN] 0020-9996
  • [Journal-full-title] Investigative radiology
  • [ISO-abbreviation] Invest Radiol
  • [Language] eng
  • [Grant] United States / NIBIB NIH HHS / EB / EB002847-02; United States / NCI NIH HHS / CA / P30 CA43703
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Delayed-Action Preparations; 0 / pluronic block copolymer p85; 9003-11-6 / Poloxalene; BG3F62OND5 / Carboplatin
  •  go-up   go-down


30. Fang M, Dewaele S, Zhao YP, Stärkel P, Vanhooren V, Chen YM, Ji X, Luo M, Sun BM, Horsmans Y, Dell A, Haslam SM, Grassi P, Libert C, Gao CF, Chen CC: Serum N-glycome biomarker for monitoring development of DENA-induced hepatocellular carcinoma in rat. Mol Cancer; 2010 Aug 12;9:215
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum N-glycome biomarker for monitoring development of DENA-induced hepatocellular carcinoma in rat.
  • We previously found that serum N-linked sugar chains are altered in hepatocellular carcinoma (HCC).
  • Here, we studied glycomic alterations during development of HCC in a rat model.
  • RESULTS: Rat HCC was induced by the hepatocarcinogen, diethylnitrosamine (DENA).
  • We thus propose a GlycoTest model using the above-mentioned serum glycan markers to monitor the progression of cirrhosis and HCC in the DENA-treated rat model.
  • When DENA-treated rats were subsequently treated with farnesylthiosalicyclic acid, an anticancer drug, progression to HCC was prevented and GlycoTest markers (P5, R5a and R5b) reverted towards non-DENA levels, and the HCC-specific markers, log(R5a/P1) and log(R5b/P1), normalized completely.
  • Our GlycoTest model can be used to monitor progression of HCC and to follow up treatment of liver tumors in the DENA rat.
  • This GlycoTest model is particularly important because a rapid non-invasive diagnostic procedure for tumour progression in this rat model would greatly facilitate the search for anticancer drugs.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. N-NITROSODIETHYLAMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatol. 1991 Nov;13(3):372-4 [1808228.001]
  • [Cites] J Biol Chem. 1989 Feb 15;264(5):2415-23 [2536709.001]
  • [Cites] Cancer Res. 1993 Nov 15;53(22):5419-23 [7693340.001]
  • [Cites] Methods Enzymol. 1994;230:108-32 [8139492.001]
  • [Cites] J Hepatol. 1995 Jan;22(1):112-4 [7751577.001]
  • [Cites] Adv Exp Med Biol. 1995;376:231-8 [8597253.001]
  • [Cites] J Biol Chem. 1997 Jan 31;272(5):2866-72 [9006930.001]
  • [Cites] Hepatology. 2005 Feb;41(2):307-14 [15660382.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2237-43 [10232614.001]
  • [Cites] Dev Biol Stand. 1998;96:43-7 [9890515.001]
  • [Cites] Methods. 2005 Apr;35(4):328-37 [15804604.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15791-6 [16236725.001]
  • [Cites] Immunol Cell Biol. 2005 Dec;83(6):674-86 [16266320.001]
  • [Cites] J Biol Chem. 2006 Feb 3;281(5):2572-7 [16316986.001]
  • [Cites] Am J Gastroenterol. 2006 Mar;101(3):513-23 [16542288.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2803-8 [16385567.001]
  • [Cites] Methods Enzymol. 2006;415:59-86 [17116468.001]
  • [Cites] J Proteome Res. 2007 May;6(5):1822-32 [17432893.001]
  • [Cites] J Biol Chem. 2007 May 25;282(21):15700-8 [17383961.001]
  • [Cites] Mol Cancer Ther. 2007 Jun;6(6):1765-73 [17541036.001]
  • [Cites] Hepatology. 2007 Nov;46(5):1426-35 [17683101.001]
  • [Cites] J Hepatol. 2008 May;48(5):858-79 [18314222.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1650-9 [18311910.001]
  • [Cites] J Biochem. 2008 Jun;143(6):725-9 [18218651.001]
  • [Cites] Biogerontology. 2008 Oct;9(5):351-6 [18431686.001]
  • [Cites] Arch Toxicol. 2008 Sep;82(9):623-31 [18204979.001]
  • [Cites] Mech Ageing Dev. 2009 Jan-Feb;130(1-2):92-7 [19070631.001]
  • [Cites] Mol Cell Proteomics. 2009 May;8(5):986-94 [19181623.001]
  • [Cites] Int J Cancer. 2010 Jul 1;127(1):148-59 [19904744.001]
  • [Cites] Liver Int. 2010 Feb;30(2):259-67 [19951379.001]
  • [Cites] Eur J Cancer. 2009 Jul;45(11):2050-60 [19427195.001]
  • [Cites] Scand J Immunol. 2000 Mar;51(3):300-6 [10736100.001]
  • [Cites] Clin Liver Dis. 2001 Feb;5(1):145-59 [11218912.001]
  • [Cites] Biochimie. 2001 Jul;83(7):557-63 [11522383.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):153-6 [11668491.001]
  • [Cites] Biomed Chromatogr. 2002 Sep;16(6):365-72 [12228891.001]
  • [Cites] J Clin Gastroenterol. 2002 Nov-Dec;35(5 Suppl 2):S72-8 [12394209.001]
  • [Cites] J Hepatol. 2003 Mar;38(3):357-60 [12586303.001]
  • [Cites] J Hepatol. 2003;38 Suppl 1:S38-53 [12591185.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6282-9 [14559815.001]
  • [Cites] Dig Liver Dis. 2004 Apr;36(4):231-42 [15115333.001]
  • [Cites] Nat Med. 2004 Apr;10(4):429-34 [15152612.001]
  • [Cites] Clin Chem. 2004 Aug;50(8):1299-300 [15277345.001]
  • [Cites] Hepatology. 1993 Jan;17(1):50-2 [7678576.001]
  • (PMID = 20704698.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United Kingdom / Biotechnology and Biological Sciences Research Council / / BBF0083091
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinogens; 0 / Polysaccharides; 3713-31-3 / Fucose; 3IQ78TTX1A / Diethylnitrosamine; EC 2.4.1.- / Fucosyltransferases
  • [Other-IDs] NLM/ PMC2925372
  •  go-up   go-down






Advertisement